Edwards notches win over Boston Sci in latest TAVR patent review
Edwards Lifesciences notched a victory in its ongoing dispute with Boston Scientific concerning transcatheter aortic valve replacement (TAVR) patents. In a March 23 release, Edwards announced the United States Patent and Trademark Office (USPTO) determined all of Boston Scientific’s claims against Edwards were invalid in an Inter Partes Review.
"We are disappointed with the U.S. Patent Office decision on the BSC Haug ‘608 seal patent, and we plan to appeal," a Boston Scientific spokesperson wrote in an email to Medical Device + Diagnostic Industry.
Read more about this latest decision—and the ongoing dispute between Edwards and Boston Scientific—at MD+DI:
Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.